CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial.

ABSTRACT:

Importance

Methotrexate is a first-line systemic agent for treating of psoriasis, although its onset of effects is slower and overall it is less effective than tumor necrosis factor blockers.

Objective

To differentiate the response of psoriatic disease to adalimumab and methotrexate sodium.

Design, setting, and participants

Single-center, randomized, assessor-blind, 2-arm clinical trial of 30 patients from the outpatient dermatology center of Tufts Medical Center, enrolled from August 18, 2009, to October 11, 2011. Patients aged 18 to 85 years with chronic plaque-type psoriasis, a minimum Physician Global Assessment score of 3 (higher scores indicate more severe disease), and a psoriatic plaque of at least 2 cm were randomized in a 1:1 fashion to receive subcutaneous

SUBMITTER: Goldminz AM 

PROVIDER: S-EPMC5788701 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature